AI Article Synopsis
Article Abstract
Renal ischemia-reperfusion injury (IRI) after renal transplantation often leads to the loss of kidney graft function. However, there is still a lack of efficient regimens to prevent or alleviate renal IRI. Our study focused on the renoprotective effect of 3-Deazaneplanocin A (DZNep), which is a histone methylation inhibitor. We found that DZNep significantly alleviated renal IRI by suppressing nuclear factor kappa-B (NF-κB), thus inhibiting the expression of inflammatory factors in renal tubular epithelial cells or . After treatment with DZNep, T cell activation was impaired in the spleen and kidney, which correlated with the downregulated expression of T-cell immunoglobulin mucin (TIM)-1 on T cells and TIM-4 in macrophages. In addition, pretreatment with DZNep was not sufficient to protect the kidney, while administration of DZNep from before to after surgery significantly ameliorated IRI. Our findings suggest that DZNep can be a novel strategy for preventing renal IRI following kidney transplantation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365856 | PMC |
| http://dx.doi.org/10.3389/fmed.2020.00305 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unveiling the intricate interplay: Exploring biological bridges between renal ischemia-reperfusion injury and T cell-mediated immune rejection in kidney transplantation.
PLoS One
December 2024
Department of Medical Records Management and Statistics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Unlabelled: Although the link between ischemia-reperfusion injury (IRI) and T cell-mediated rejection (TCMR) in kidney transplantation (KT) is well known, the mechanism remains unclear. We investigated essential genes and biological processes involved in interactions between IRI and TCMR.
Methods: Renal IRI and TCMR datasets were obtained from the Gene Expression Omnibus database.
Lysozyme-targeted liposomes for enhanced tubular targeting in the treatment of acute kidney injury.
Acta Biomater
December 2024
The State Key Laboratory of Functions and Applications of MediEucal Plants, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang 550025, Guizhou Province, China; The Guizhou Provincial Scientific and Technologic Innovation Base ([2023]003), Guizhou Medical University, Guiyang 550025, Guizhou Province, China. Electronic address:
Acute kidney injury (AKI) is defined by the release of pro-inflammatory factors, leading to structural damage in renal tubules and subsequent tubular cell injury and death. Delivering drugs specifically to renal tubules to mitigate tubular cell damage holds potential for AKI treatment. In this work, we developed functional liposomes (LZM-PLNPs-TP) designed to bypass the glomerular filtration barrier and target tubules by leveraging the unique structural and pathological characteristics of glomeruli and tubules.
View Article and Find Full Text PDFIdentification of Renal Ischemia-Reperfusion Injury Subtypes and Predictive Model for Graft Loss after Kidney Transplantation Based on Programmed Cell Death-Related Genes.
Kidney Dis (Basel)
December 2024
Renal Division, Peking University Institute of Nephrology, Key Laboratory of Renal Disease-Ministry of Health of China, Key Laboratory of CKD Prevention and Treatment (Peking University)-Ministry of Education of China, Peking University First Hospital, Beijing, China.
Introduction: Ischemia-reperfusion injury (IRI) is detrimental to kidney transplants and may contribute to poor long-term outcomes of transplantation. Programmed cell death (PCD), a regulated cell death form triggered by IRI, is often indicative of an unfavorable prognosis following transplantation. However, given the intricate pathophysiology of IRI and the considerable variability in clinical conditions during kidney transplantation, the specific patterns of cell death within renal tissues remain ambiguous.
View Article and Find Full Text PDFAn Experimental Insight Into the Role of Agomelatine in Renal Ischemia/Reperfusion Injury.
J Biochem Mol Toxicol
December 2024
Department of Physiology, Faculty of Medicine, İnönü University, Malatya, Turkey.
Acute kidney injury (AKI) is one of the leading causes of chronic kidney disease and accounts for 50%-75% of mortality following renal pathologies or organ transplantation. Ischemia‒reperfusion injury (IRI) involves an interrupted blood supply to organs and the kidney; IRI exacerbates AKI development. Owing to several pharmacological treatment methods, AKI still has a poor prognosis, and novel therapeutic options are needed.
View Article and Find Full Text PDFMetabolomic and transcriptomic insights into the mechanisms of renal ischemia-reperfusion injury progression.
Sci Rep
December 2024
Department of Clinical Laboratory, School of Medicine, Mianyang Central Hospital, University of Electronic Science and Technology of China, Mianyang, 621000, Sichuan, China.
Article Synopsis
- - The study investigates renal ischemia-reperfusion injury (IRI) as a major cause of acute kidney injury (AKI), utilizing a combination of metabolomics and transcriptomics to understand the underlying mechanisms of IRI-AKI progression.
- - Researchers created rat models simulating IRI-AKI through 30 minutes of ischemia followed by 24-72 hours of reperfusion, finding significant decreases in key metabolites, especially in amino acids, organic acids, and carnitines compared to control groups.
- - The results highlighted that specific pathways related to the metabolism of valine, leucine, and isoleucine are significantly impacted, suggesting these pathways may be critical in linking genetic (transcriptomic) and metabolic (metabol
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!